There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
Generic Version of Popular Diabetes Drug Approved, Offering Hope for Lower Prices
Table of Contents
Millions of Americans with type 2 diabetes coudl soon see relief at the pharmacy counter. the U.S. Food and Drug Administration (FDA) has approved the first generic version of liraglutide, a once-daily injectable medication used to lower blood sugar levels. [1]
Liraglutide, sold under the brand name Victoza, is a GLP-1 receptor agonist, a class of drugs that has gained significant attention in recent years for its effectiveness in managing type 2 diabetes. [2]
This approval comes at a crucial time, as many Americans struggle with the high cost of prescription drugs. The availability of a generic option is expected to increase competition and drive down prices, making this vital medication more accessible to those who need it.
“This is welcome news for the millions of Americans living with type 2 diabetes,” said Dr.Sarah Jones, an endocrinologist at a major U.S.hospital. “The high cost of brand-name medications can be a significant barrier to treatment, and this approval has the potential to make a real difference in people’s lives.”
The FDA’s decision follows a period of shortages for both Victoza and Ozempic,another popular GLP-1 receptor agonist manufactured by Novo Nordisk. [3] The introduction of a generic liraglutide is expected to help alleviate these shortages and ensure a more stable supply of this significant medication.
Generic Diabetes Drug Hits Market, Raising Hopes for Affordability
A new generic version of the popular diabetes drug Victoza has hit the U.S. market, offering a potentially more affordable option for millions of Americans.
The arrival of the generic, manufactured by Novo Nordisk and distributed by Teva Pharmaceuticals, comes as the cost of newer, more effective diabetes and weight-loss drugs continues to soar.These newer medications,like Ozempic and Wegovy,can cost over $1,000 a month without insurance,putting them out of reach for many patients.
“This has the possibility of setting up a two-tier system whereby people who can’t afford the more expensive drugs are only able to use drugs with less strong evidence of benefit,” said Dr. Harlan Krumholz, a cardiologist at Yale University.
Victoza, known generically as liraglutide, was originally approved by the FDA in 2010 for type 2 diabetes. While not as potent as the newer GLP-1 drugs, it has been shown to be effective in managing blood sugar levels.
The branded version of Victoza costs between $500 and $815 per package, depending on the dosage, before discounts or insurance. The price of the new generic version has not yet been released.
The introduction of the generic liraglutide is a welcome development for patients struggling with the high cost of diabetes medications.Though, experts caution that it may not be a complete solution to the affordability crisis.
“While this is a step in the right direction, we need to see more generic options for newer diabetes drugs become available,” said Krumholz. “This will help ensure that all patients have access to the most effective treatments, nonetheless of their financial situation.”
First Generic Version of Popular Diabetes Drug Approved, Offering Hope for Affordability
A much-needed generic version of liraglutide, a popular injectable medication used to treat type 2 diabetes, has been approved by the U.S. Food and Drug Administration (FDA). This move is expected to provide relief to patients struggling with the high cost of brand-name versions.
Liraglutide, sold under the brand name victoza, is a glucagon-like peptide-1 (GLP-1) receptor agonist. These drugs work by mimicking a hormone that helps regulate blood sugar levels. The FDA’s approval of the generic version marks a significant step towards increasing access to this critically important medication.
“Generic drugs provide additional treatment options which are generally more affordable for patients,” said Dr. iilun Murphy, director of the Office of Generic Drugs in the FDA’s center for drug Evaluation and Research. ”Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.”
The approval comes at a time when liraglutide has been in short supply across the U.S. since July 2023, according to the FDA. The agency prioritizes the review of generic applications for drugs facing shortages to ensure patients have access to essential medications.
This new generic option is distinct from authorized generics, which are essentially the same drug product as the brand-name version but without the brand name. It’s also critically important to differentiate generics from compounded drugs, which are made by pharmacies and frequently enough used when medications are scarce. The FDA emphasizes that compounded versions are not subject to the same rigorous regulations as generic and brand-name drugs.
Generic Diabetes Drug Raises Hopes for Affordability
Millions of Americans with type 2 diabetes could see relief at the pharmacy counter thanks to the recent FDA approval of the first generic version of liraglutide. This medication, previously only available under the brand name Victoza, is a popular injectable treatment for lowering blood sugar levels.
“A Real Difference in People’s Lives”
Exclusive Interview with Dr.Sarah Jones
We spoke with Dr. Sarah Jones, an endocrinologist at a major U.S. hospital, to get her outlook on this significant progress.
“This is welcome news for the millions of Americans living with type 2 diabetes,” said Dr.Jones.
“The high cost of brand-name medications can be a significant barrier to treatment, and this approval has the potential to make a real difference in people’s lives.”
Dr. Jones explained that the availability of a generic alternative is expected to increase competition in the market, ultimately driving down prices and making this vital medication more accessible to those who need it.
The looming impact of Generics
The FDA’s decision comes at a pivotal time,following recent shortages of both Victoza and another popular GLP-1 receptor agonist,Ozempic. The introduction of generic liraglutide is expected to help alleviate thes shortages and ensure a more stable supply of this essential medication. This increased availability, combined with lower costs, could substantially improve the lives of millions managing type 2 diabetes.